| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
V-9-M Cholecystokinin nonapeptide targets cholecystokinin (CCK) receptors. As a CCK analog, it binds to CCK1 and CCK2 receptors (formerly CCK-A and CCK-B) to modulate gastrointestinal motility, pancreatic enzyme secretion, and satiety signaling in the central nervous system. The compound is used in research to study the physiological roles of CCK in digestion and appetite regulation.
|
|---|---|
| ln Vitro |
Detailed in vitro activity data for V-9-M Cholecystokinin nonapeptide are not extensively available. As a CCK receptor agonist, it would be expected to activate CCK receptors in cell-based assays, stimulating signaling pathways such as phospholipase C and intracellular calcium mobilization. Binding affinity and functional potency would be determined using receptor binding and second messenger assays.
|
| ln Vivo |
Detailed in vivo activity data for V-9-M Cholecystokinin nonapeptide are not extensively available. As a CCK analog, it would be expected to produce CCK-like effects including stimulation of pancreatic secretion, gallbladder contraction, and inhibition of gastric emptying in animal models. These effects are consistent with the known physiological functions of cholecystokinin.
|
| Enzyme Assay |
Specific cell-free enzyme/receptor binding assay protocols for V-9-M Cholecystokinin nonapeptide involve radioligand binding assays using membranes expressing CCK1 or CCK2 receptors. Binding affinity (Ki or Kd) is determined by competitive displacement of a radiolabeled CCK ligand. Receptor selectivity can be assessed by comparing binding to CCK1 versus CCK2 receptors.
|
| Cell Assay |
Specific in vitro cell-based experimental protocols for V-9-M Cholecystokinin nonapeptide use cell lines expressing CCK receptors. Cells are treated with the peptide, and receptor activation is assessed by measuring intracellular calcium mobilization, inositol phosphate accumulation, or other downstream signaling events. Functional potency (EC50) is determined from concentration-response curves.
|
| Animal Protocol |
Specific in vivo animal experimental protocols for V-9-M Cholecystokinin nonapeptide involve administration to rodents to assess CCK-like effects. Endpoints include measurement of pancreatic secretion, gallbladder contraction, gastric emptying, and food intake. The compound’s effects on satiety and gastrointestinal motility can be evaluated in these models.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic properties of V-9-M Cholecystokinin nonapeptide are not extensively available. As a peptide, it would be expected to have limited oral bioavailability and rapid degradation by proteolytic enzymes. Pharmacokinetic studies would typically involve intravenous or subcutaneous administration with measurement of plasma concentrations using immunoassay or HPLC-MS methods.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for V-9-M Cholecystokinin nonapeptide are not extensively available. As a research peptide, standard toxicology studies would be required for therapeutic development. The compound is classified for research use only and is not intended for human therapeutic applications.
|
| References | |
| Additional Infomation |
V-9-M Cholecystokinin nonapeptide (CAS 99291-20-0) is a research peptide used in neuroscience and gastrointestinal research to study CCK receptor function. Cholecystokinin is a peptide hormone that regulates digestion, satiety, and pancreatic secretion. The compound is supplied for research use only and is not intended for human therapeutic applications. No clinical trial or approved indication data are available.
|
| Molecular Formula |
C42H69N9O14S
|
|---|---|
| Molecular Weight |
956.12
|
| Exact Mass |
955.468
|
| CAS # |
99291-20-0
|
| PubChem CID |
5489386
|
| Sequence |
VPVEAVDPM
|
| Appearance |
White to off-white solid powder
|
| Density |
1.306g/cm3
|
| Boiling Point |
1350.706°C at 760 mmHg
|
| Flash Point |
770.679°C
|
| LogP |
1.291
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
26
|
| Heavy Atom Count |
66
|
| Complexity |
1800
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)NC(=O)C2CCCN2C(=O)[C@H](C(C)C)N
|
| InChi Key |
AIKMAJWJXJPJNB-MHJJKFOESA-N
|
| InChi Code |
InChI=1S/C42H69N9O14S/c1-20(2)31(43)41(63)51-17-10-12-28(51)37(59)49-33(22(5)6)38(60)45-24(13-14-29(52)53)35(57)44-23(7)34(56)48-32(21(3)4)39(61)47-26(19-30(54)55)40(62)50-16-9-11-27(50)36(58)46-25(42(64)65)15-18-66-8/h20-28,31-33H,9-19,43H2,1-8H3,(H,44,57)(H,45,60)(H,46,58)(H,47,61)(H,48,56)(H,49,59)(H,52,53)(H,54,55)(H,64,65)/t23-,24-,25-,26-,27-,28?,31-,32-,33-/m0/s1
|
| Chemical Name |
(4S)-4-[[(2S)-2-[[1-[(2S)-2-amino-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[(2S)-2-[[(1S)-1-carboxy-3-methylsulfanylpropyl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
|
| Synonyms |
V 9 M; V-9-M; V-9-M Cholecystokinin nonapeptide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~104.59 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.61 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.61 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0459 mL | 5.2295 mL | 10.4589 mL | |
| 5 mM | 0.2092 mL | 1.0459 mL | 2.0918 mL | |
| 10 mM | 0.1046 mL | 0.5229 mL | 1.0459 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
